New! Create a free account on OpenAnesthesia.org!
We want to know more about you to create the content you seek!
Health Equity Curriculum for Anesthesia Residents
OA-SPA Ask the Expert - October 2024
New! Spanish-Language Summaries! ¡Nuevo! ¡Resúmenes en español!
Quizzes follow each summary. Los cuestionarios siguen a cada resumen.
Check out the latest OpenAnesthesia Summaries!
More than 360 mini-reviews on high-yield topics in anesthesiology, critical care, and perioperative medicine.
Question of the Day
Which of the following laboratory values contribute MOST to the model for end-stage liver disease (MELD) scoring system?
Explanation
The Model for End-Stage Liver Disease (MELD) scoring system was originally used to estimate 3-month survival after elective transjugular intrahepatic portosystemic shunt placement. In an effort to more objectively allocate organs, MELD was adopted to determine priority for organ placement for patients with end-stage liver disease. Prior to the MELD-based system, allocation was based on time on the waiting list as well as the Child-Turcotte Pugh scoring system, which used more subjective measurements of liver disease such as degree of encephalopathy and ascites. This created an incentive to list patients earlier with organs being placed in less sick individuals. The MELD score takes into account serum bilirubin, the international normalized ratio (INR) and serum creatinine. Coexistent renal disease (whether hepatorenal syndrome or renal failure as a result of liver failure) is more heavily weighted in the MELD score. Additionally, MELD exception points have been assigned to patients who have more severe liver disease that may not be reflected in the basic MELD score including sodium, hepatopulmonary syndrome and hepatocellular carcinoma. MELD= 3.78xln[serum bilirubin (mg/dL)] + 11.2xln(INR) + 9.57xln[serum creatinine(mg/dL)] + 6.43
References:
Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31(4):864-871. doi:10.1053/he.2000.5852 Kamath PS, Kim WR; Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology. 2007;45(3):797-805. doi:10.1002/hep.21563 Liver Disease Scoring SystemsOA Series: October 2024
35:32
OA Global Health Equity Ask the Expert
Health Equity Curriculum for Anesthesia ResidentsSamuel Percy, MD, Children's Hospital Colorado, Aurora, CO
Copy link